Dinalbuphine Sebacate in Postoperative Pain Control After TKA

Launched by THAMMASAT UNIVERSITY · Aug 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well a medicine called Dinalbuphine Sebacate works to control pain after knee replacement surgery (also called total knee arthroplasty) in people with knee osteoarthritis. The goal is to see if this medicine can help manage the pain that happens in the weeks following surgery, making recovery more comfortable.

People who might be eligible to join the study are adults between 50 and 90 years old who have osteoarthritis in one knee and are having their first knee replacement on that knee. They should be generally healthy enough for surgery (classified as ASA class I to III) and able to understand and agree to the study rules. Some people won’t be able to join if they have very severe obesity, certain other knee problems, previous knee surgery, liver disease, allergies to specific medicines or ingredients, or if they are taking certain drugs that affect how the body processes medications. Participants can expect to be closely monitored for pain after their surgery while receiving the study treatment. This trial has not started recruiting yet, so if you or a loved one are interested, it’s good to keep an eye out for when enrollment opens.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Osteoarthritic knee patients underwent unilateral primary TKA
• • Age 50-90 years
• • ASA class I-III
• • Participants understand and consent to the protocol of the trial
• Exclusion Criteria:
• • Morbid obesity (BMI\>40)
• • Knee osteoarthritis from inflammatory knee arthritis, trauma, infection
• • Previous knee surgery
• • Cognitive disorder
• • Liver disease
• • Allergy to NSAIDs, opioids, sesame oil, and benzyl benzoate
• • CYP3A4 inhibitor and inducer drugs used